Treatment Options For Postmenopausal Women with Tamoxifen-Resistant Advanced Breast Cancer

American Journal of Cancer ◽

10.2165/00024669-200201040-00006 ◽

2002 ◽

Vol 1 (4) ◽

pp. 293-300 ◽

Author(s):

Kwok-Leung Cheung ◽

John F.R. Robertson

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Treatment Options ◽

Advanced Breast ◽

Tamoxifen Resistant

Download Full-text

Ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative advanced breast cancer (ABC) who received no prior therapy for advanced disease

Geburtshilfe und Frauenheilkunde ◽

10.1055/s-0036-1592812 ◽

2016 ◽

Vol 76 (10) ◽

Author(s):

EM Grischke ◽

A Nusch ◽

N Marschner ◽

W Abenhardt ◽

J Wilke ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Advanced Disease ◽

Advanced Breast ◽

Prior Therapy ◽

Hormone Receptor Positive

Download Full-text

Faculty Opinions recommendation of Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR+, HER2- Advanced Breast Cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.738775672.793581181 ◽

2020 ◽

Author(s):

Jason S Carroll

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Dose Escalation ◽

Advanced Breast ◽

Download Full-text

Clinical Trial of Letrozole (femara) versus Aminoglutethimide in Postmenopausal Women with Advanced Breast Cancer

The Chinese-German Journal of Clinical Oncology ◽

10.1007/s10330-005-0387-4 ◽

2005 ◽

Vol 4 (6) ◽

pp. 338-340

Author(s):

Xiaoqing LIU ◽

Santai SONG ◽

Zefei JIANG ◽

Weilian LI ◽

Weixia WANG ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Advanced Breast

Download Full-text

Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice

Clinical & Translational Oncology ◽

10.1007/s12094-017-1797-9 ◽

2017 ◽

Vol 20 (7) ◽

pp. 862-869 ◽

Author(s):

I. Blancas ◽

M. Fontanillas ◽

V. Conde ◽

J. Lao ◽

E. Martínez ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Practice ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Routine Clinical Practice ◽

Advanced Breast

Download Full-text

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2

Annals of Oncology ◽

10.1093/annonc/mdu009 ◽

2014 ◽

Vol 25 (4) ◽

pp. 808-815 ◽

Author(s):

H.S. Rugo ◽

K.I. Pritchard ◽

M. Gnant ◽

S. Noguchi ◽

M. Piccart ◽

...

Keyword(s):

Breast Cancer ◽

Adverse Events ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Time Course ◽

Advanced Breast ◽

Hormone Receptor Positive

Download Full-text

The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial

Journal of Bone Oncology ◽

10.1016/j.jbo.2018.09.010 ◽

2019 ◽

Vol 14 ◽

pp. 100199 ◽

Author(s):

Peyman Hadji ◽

Oliver Stoetzer ◽

Thomas Decker ◽

Christian M. Kurbacher ◽

Frederik Marmé ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Bone Health ◽

Hormone Receptor ◽

Mammalian Target Of Rapamycin ◽

Advanced Breast ◽

Hormone Receptor Positive ◽

Download Full-text

Survival advantage of exemestane (EXE, Aromasin®) over megestrol acetate (MA) in postmenopausal women with advanced breast cancer (ABC) refractory to tamoxifen (TAM): results of a phase III randomized double-blind study

European Journal of Cancer ◽

10.1016/s0959-8049(99)80705-9 ◽

1999 ◽

Vol 35 ◽

pp. S84 ◽

Author(s):

E. Bajetta ◽

L.Y. Dirix ◽

L.E. Fein ◽

S.E. Jones ◽

J. Cervek ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Survival Advantage ◽

Advanced Breast ◽

Blind Study ◽

Megestrol Acetate ◽

Phase Iii ◽

Double Blind Study ◽

Download Full-text

Anastrozole (Arimidex™) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results

European Journal of Cancer ◽

10.1016/s0959-8049(03)00326-5 ◽

2003 ◽

Vol 39 (12) ◽

pp. 1684-1689 ◽

Author(s):

J.M Nabholtz ◽

J Bonneterre ◽

A Buzdar ◽

J.F.R Robertson ◽

B Thürlimann

Keyword(s):

Breast Cancer ◽

Survival Analysis ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Advanced Breast ◽

First Line Therapy ◽

Download Full-text

First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2− advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial

Breast Cancer Research and Treatment ◽

10.1007/s10549-017-4658-x ◽

2018 ◽

Vol 169 (3) ◽

pp. 469-479 ◽

Author(s):

Wolfgang Janni ◽

Emilio Alba ◽

Thomas Bachelot ◽

Sami Diab ◽

Miguel Gil-Gil ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Tumor Response ◽

Pain Reduction ◽

Advanced Breast ◽

Phase 3 ◽

Download Full-text

Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR+, HER2− Advanced Breast Cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-20-1068 ◽

2020 ◽

Vol 26 (24) ◽

pp. 6417-6428

Author(s):

Aditya Bardia ◽

Shanu Modi ◽

Mafalda Oliveira ◽

Javier Cortes ◽

Mario Campone ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Dose Escalation ◽

Advanced Breast ◽

Download Full-text